In solid malignancies, including hepatocellular carcinoma [7, 8], uveal melanoma [10, 11], osteosarcoma [15], bladder cancer [16], and breast carcinoma [18], high PRAME expression correlates with advanced-stage disease and poor survival, whereas in pediatric acute leukemia, PRAME overexpression was found to predict good outcome [20–22]. This evidence concerns the gene PRAME and uveal melanoma.